These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 14762574)
1. Immunological effects of donor lymphocyte infusion in patients with chronic myelogenous leukemia relapsing after bone marrow transplantation. Castro FA; Palma PV; Morais FR; Voltarelli JC Braz J Med Biol Res; 2004 Feb; 37(2):201-6. PubMed ID: 14762574 [TBL] [Abstract][Full Text] [Related]
2. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710 [TBL] [Abstract][Full Text] [Related]
3. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. Sehn LH; Alyea EP; Weller E; Canning C; Lee S; Ritz J; Antin JH; Soiffer RJ J Clin Oncol; 1999 Feb; 17(2):561-8. PubMed ID: 10080600 [TBL] [Abstract][Full Text] [Related]
4. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease? Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E; Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175 [TBL] [Abstract][Full Text] [Related]
5. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation. Chiorean EG; DeFor TE; Weisdorf DJ; Blazar BR; McGlave PB; Burns LJ; Brown C; Miller JS Biol Blood Marrow Transplant; 2004 Mar; 10(3):171-7. PubMed ID: 14993882 [TBL] [Abstract][Full Text] [Related]
6. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886 [TBL] [Abstract][Full Text] [Related]
7. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003 [TBL] [Abstract][Full Text] [Related]
8. Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia: a therapeutic strategy. Novitzky N; Rubinstein R; Hallett JM; du Toit CE; Thomas VL Transplantation; 2000 Apr; 69(7):1358-63. PubMed ID: 10798754 [TBL] [Abstract][Full Text] [Related]
9. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Giralt S; Hester J; Huh Y; Hirsch-Ginsberg C; Rondón G; Seong D; Lee M; Gajewski J; Van Besien K; Khouri I; Mehra R; Przepiorka D; Körbling M; Talpaz M; Kantarjian H; Fischer H; Deisseroth A; Champlin R Blood; 1995 Dec; 86(11):4337-43. PubMed ID: 7492795 [TBL] [Abstract][Full Text] [Related]
10. In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion. Schattenberg A; Schaap N; Van De Wiel-Van Kemenade E; Bär B; Preijers F; Van Der Maazen R; Roovers E; De Witte T Leuk Lymphoma; 1999 Jan; 32(3-4):317-25. PubMed ID: 10037029 [TBL] [Abstract][Full Text] [Related]
11. Donor lymphocyte infusion followed by interferon-alpha plus low dose cyclosporine A for modulation of donor CD3 cells activity with monitoring of minimal residual disease and cellular chimerism in a patient with first hematologic relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation. Leda M; Ladon D; Pieczonka A; Boruczkowski D; Jólkowska J; Witt M; Wachowiak J Leuk Res; 2001 Apr; 25(4):353-7. PubMed ID: 11248334 [TBL] [Abstract][Full Text] [Related]
12. Immunological effects of interferon-alpha on chronic myelogenous leukemia. de Castro FA; Palma PV; Morais FR; Simões BP; Carvalho PV; Ismael SJ; Lima CP; Voltarelli JC Leuk Lymphoma; 2003 Dec; 44(12):2061-7. PubMed ID: 14959848 [TBL] [Abstract][Full Text] [Related]
13. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells. Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267 [TBL] [Abstract][Full Text] [Related]
14. Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program. Miyamoto T; Fukuda T; Nakashima M; Henzan T; Kusakabe S; Kobayashi N; Sugita J; Mori T; Kurokawa M; Mori SI Biol Blood Marrow Transplant; 2017 Jun; 23(6):938-944. PubMed ID: 28219836 [TBL] [Abstract][Full Text] [Related]
15. The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions? Zeidner JF; Zahurak M; Rosner GL; Gocke CD; Jones RJ; Smith BD Leuk Lymphoma; 2015 Jan; 56(1):128-34. PubMed ID: 24712979 [TBL] [Abstract][Full Text] [Related]
16. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation. Román J; Alvarez MA; Torres A Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600 [TBL] [Abstract][Full Text] [Related]
17. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403 [TBL] [Abstract][Full Text] [Related]
18. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408 [TBL] [Abstract][Full Text] [Related]
19. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice. Du B; Li DP; Xu KL; Pan XY Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128 [TBL] [Abstract][Full Text] [Related]
20. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]